Recurrent Respiratory Papillomatosin Foundation Inc - NJ Mercer, Trenton 08648

Recurrent Respiratory Papillomatosin Foundation Inc entered the industry of Medical Research in 1992 and has grown to employ 1 to 4 people, generating an annual revenue of $0 to $49.999. The NAICS classifies this business under the code 541720, which describes it as a Medical Research. For further clarification, the SIC classifies this business under the code 8733 and described it as a Medical Research. The business provides service to the B2B market.

To acquire more information, please contact Marlene Stern by calling (609) 530-1443 during business hours. You can also write to the business’ Single Location at 12 Ashwood Court, Trenton, New Jersey NJ 08648. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .

Company: Recurrent Respiratory Papillomatosin Foundation Inc
Representative: Marlene Stern
Place of Business: 12 Ashwood Court, Trenton, NJ 08648
Contact Number: (609) 530-1443
Type of Service: Medical Research
SIC Number: 8733
NAICS Number: 541720
Locality: Single Location
Market Type: B2B (Business to Business)
Began: 1992
Income/Year: $0 to $49.999
Laborers: 1 to 4
Share This Company:

Recurrent Respiratory Papillomatosin Foundation Inc is a company operating from Mercer, New Jersey providing professional Medical Research and relevant B2B variables. It was founded in 1992 and registered with the SIC code 8733 as Medical Research, and with the NAICS code 541720 as Medical Research.

With a current employee count of 1 to 4, Recurrent Respiratory Papillomatosin Foundation Inc has gone to report making $0 to $49.999 per annum on its journey towards growth. This company invites you to contact its representative Marlene Stern at (609) 530-1443 for related queries, or to locate its Single Location using the coordinates 40.310179,-74.724284.

The Single Location can also be found at the street address 12 Ashwood Court in Trenton, New Jersey 08648 and can be engaged online through the company website at , the company Twitter , and Facebook page .